WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 326939
CAS#: 159912-58-0 (HCl)
Description: Sabcomeline, also known as BCI-224; BRL-55473; CEB-2424; SB-202026A, is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease. It made it to phase III clinical trials before being discontinued due to poor results.
MedKoo Cat#: 326939
Name: Sabcomeline HCl
CAS#: 159912-58-0 (HCl)
Chemical Formula: C10H16ClN3O
Exact Mass: 229.0982
Molecular Weight: 229.708
Elemental Analysis: C, 52.29; H, 7.02; Cl, 15.43; N, 18.29; O, 6.96
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 159912-58-0 (HCl) 159912-53-5(free base)
Synonym: Sabcomeline hydrochloride; BCI-224; BRL-55473; CEB-2424; SB-202026A; BCI224; BRL55473; CEB2424; SB202026A. Memric.
IUPAC/Chemical Name: (R)-3-Quinuclidineglyoxylonitrile (Z)-O-methyloxime, monohydrochloride
InChi Key: INJWRVWKJFJRFO-SCRZZQONSA-N
InChi Code: InChI=1S/C10H15N3O.ClH/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13;/h8-9H,2-5,7H2,1H3;1H/b12-10+;/t9-;/m0./s1
SMILES Code: N#C/C([C@H]1CN2CCC1CC2)=N\OC.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 229.708 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: McArthur RA, Gray J, Schreiber R. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. Curr Opin Investig Drugs. 2010 Jul;11(7):740-60. Review. PubMed PMID: 20571970.
2: Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. doi: 10.1016/j.ejphar.2008.12.044. Epub 2009 Jan 11. PubMed PMID: 19168056.
3: Li Z, Snigdha S, Roseman AS, Dai J, Meltzer HY. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Eur J Pharmacol. 2008 Oct 31;596(1-3):89-97. doi: 10.1016/j.ejphar.2008.08.009. Epub 2008 Aug 22. PubMed PMID: 18771666.
4: Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther. 2005 Mar;312(3):1055-63. Epub 2004 Dec 1. PubMed PMID: 15574685.
5: Balasubramanian A, Ganju RK, Groopman JE. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem. 2003 Sep 12;278(37):35755-66. Epub 2003 Jun 24. PubMed PMID: 12824191.
6: Hosoi R, Kobayashi K, Ishida J, Yamaguchi M, Inoue O. Effect of sabcomeline on muscarinic and dopamine receptor binding in intact mouse brain. Ann Nucl Med. 2003 Apr;17(2):123-30. PubMed PMID: 12790361.
7: Wienrich M, Meier D, Ensinger HA, Gaida W, Raschig A, Walland A, Hammer R. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci. 2001 Apr 27;68(22-23):2593-600. PubMed PMID: 11392631.
8: Stengel PW, Cohen ML. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. J Pharmacol Exp Ther. 2001 Mar;296(3):818-24. PubMed PMID: 11181912.
9: Hodges H, Peters S, Gray JA, Hunter AJ. Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area. Behav Brain Res. 1999 Feb 15;99(1):81-92. PubMed PMID: 10512575.
10: Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol. 1999 Apr;126(7):1620-4. PubMed PMID: 10323594; PubMed Central PMCID: PMC1565933.
11: Watson JM, Hunter AJ, Brown AM, Middlemiss DN. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes. Eur J Pharmacol. 1999 Apr 1;370(1):69-77. PubMed PMID: 10323282.
12: Hatcher JP, Loudon JM, Hagan JJ, Clark MS. Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Psychopharmacology (Berl). 1998 Aug;138(3-4):275-82. PubMed PMID: 9725749.
13: Harries MH, Samson NA, Cilia J, Hunter AJ. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. Br J Pharmacol. 1998 May;124(2):409-15. PubMed PMID: 9641560; PubMed Central PMCID: PMC1565397.
14: Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink-Jensen A, Sauerberg P. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 1998 Jun 8;795(1-2):179-90. PubMed PMID: 9622623.
15: Loudon JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, Riley GJ, Noy G, Orlek BS. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther. 1997 Dec;283(3):1059-68. PubMed PMID: 9399977.
16: Bromidge SM, Brown F, Cassidy F, Clark MS, Dabbs S, Hadley MS, Hawkins J, Loudon JM, Naylor CB, Orlek BS, Riley GJ. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. J Med Chem. 1997 Dec 19;40(26):4265-80. PubMed PMID: 9435896.